nivolumab + hyaluronidase-nvhy

Nivolumab + hyaluronidase-nvhy (Opdivo Qvantig) is a subcutaneous coformulation developed by Bristol Myers Squibb. It combines nivolumab, a fully human IgG4 monoclonal antibody targeting the programmed cell death receptor-1 (PD-1), with recombinant human hyaluronidase-nvhy, an enzyme that facilitates drug absorption by degrading hyaluronic acid in the subcutaneous extracellular matrix. By blocking the PD-1 receptor on T-cells, nivolumab prevents tumor-expressed PD-L1 and PD-L2 from suppressing the immune response, thereby restoring the immune system's ability to attack cancer cells. Approved by the FDA in December 2024, this formulation allows for a 3–5 minute subcutaneous injection, providing a more convenient alternative to the intravenous administration of nivolumab across various solid tumor indications, including melanoma, non-small cell lung cancer, and renal cell carcinoma.

Brand names

Opdivo Qvantig

Other names

nivolumab and hyaluronidase-nvhy